• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Adopts ICH E19 Guidelines on Selective Safety Data Gathering

FDA Adopts ICH E19 Guidelines on Selective Safety Data Gathering

December 12, 2022

In an effort to improve the efficiency of late-stage and post-approval trials, the FDA has endorsed the International Council for Harmonization’s (ICH) E19 guidelines, which offer considerations for selectively collecting safety data, in final guidance published Monday.

In the view of the FDA, selective safety data collection — the reduced collection of certain safety data after careful, thoughtful consideration — can lead to greater productivity in trials and enable larger-scale research efforts. The ICH E19 guidelines, titled “A Selective Approach to Safety Data Collection in Specific Late-Stage Pre-Approval or Post-Approval Clinical Trials,” mainly pertains to safety data in interventional post-approval trials but may be applicable in phase 3 trials in certain instances.

In situations where there is strong understanding and documentation of a drug’s safety profile, gathering comprehensive safety data may only add limited clinical knowledge, the FDA’s final guidance explains. In these circumstances, a more thought out and selective safety data gathering approach may be useful.

“By tailoring the method and streamlining the approach to safety data collection, it may be possible to carry out clinical trials with greater efficiency. This may facilitate the conduct of large-scale efficacy and safety clinical trials with large numbers of participants and long-term follow-up,” the FDA said.

The guidance goes into general principles, such as on justifying selective safety data collection, ensuring the safety of participants, data that should generally be collected and benefit-risk factors to consider when selectively gathering data, as well as sections on implementing a more selective approach, practical considerations and how ICH E19 should be considered alongside other guidances and regulations.

The EMA was the first ICH regulatory agency member to endorse the ICH E19 guidelines, doing so at the end of November (CenterWatch Weekly, Nov. 30).

Read the final guidance here: https://bit.ly/3VTADjW.

 

To view more CenterWatch Weekly stories, click here.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing